CRBU AI Price Prediction

Caribou Biosciences (CRBU) is trading at $1.97 on NASDAQ, following a sharp 4.8% single-session decline that has drawn incremental trader attention. Volume came in at approximately 1,792,942 shares — roughly 1.1 times the stock's average — suggesting the price move is generating modest but measurable market activity. With a market capitalization of $195.4 million, CRBU remains a micro-cap clinical-stage name, operating in the capital-intensive genome-edited allogeneic cell therapy space. The combination of a sub-$2 price point and elevated relative volume makes this a stock worth monitoring closely for near-term directional momentum.

TrendEdge's AI system assigns CRBU a score of 4 out of 10, reflecting a cautious outlook based on current quantifiable signals. The 4.8% price decline triggered short-term trader attention, and volume running at 1.1x normal levels confirms that activity is slightly elevated — but neither signal is strong enough to shift the AI's overall assessment into positive territory. Notably, Reddit social mentions registered zero activity in the past 24 hours, removing any retail sentiment tailwind. Volatility is running at just 0.7 times normal levels, indicating the price move, while notable, is occurring in a relatively subdued volatility environment rather than a high-conviction breakout or breakdown.

The key catalysts for CRBU center on clinical progression. CB-010 is currently in a Phase 1 trial for relapsed or refractory B cell non-Hodgkin lymphoma, while CB-011 targets relapsed or refractory multiple myeloma. Trial readouts from either program could significantly re-rate the stock in either direction. With only 2 active job postings, hiring activity is minimal, suggesting the company is not in an active operational expansion phase. Cash runway management and data milestones are the primary variables investors should track in 2026.